---
figid: PMC12018449__fphar-16-1528208-g001
figtitle: AS-IV in the pathogenesis of arrhythmia
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12018449
filename: fphar-16-1528208-g001.jpg
figlink: /pmc/articles/PMC12018449/figure/F1/
number: F1
caption: Mechanisms of AS-IV in the pathogenesis of arrhythmia. Astragaloside IV exhibits
  anti-ischemia-reperfusion injury, anti-ion channel disorder, and anti-myocardial
  fibrosis effects through maintaining mitochondrial quality control, counteracting
  oxidative stress, exerting anti-inflammatory actions, and resisting apoptosis. It
  is capable of inhibiting the expression of Drp1, decreasing the release of Cyt C,
  influencing the opening of mPTP pores, suppressing mitochondrial fission and fragmentation,
  and preserving the integrity of mitochondrial structure and function. It can activate
  the PI3K/AKT//Nrf2/ARE signaling pathway, enhance the expression and nuclear translocation
  efficiency of Nrf2, initiate the expression of downstream antioxidant factors, and
  alleviate oxidative stress. It can restrain the activation of the NF-κB/TLR4/NLPR3
  signaling pathway, reduce the expression of downstream inflammatory factors, and
  mitigate inflammation. It can inhibit the caspase pathway, regulate the expression
  of Bcl-2/bax, and decrease cardiomyocyte apoptosis
papertitle: 'Therapeutic potential and mechanistic insights of astragaloside IV in
  the treatment of arrhythmia: a comprehensive review'
reftext: Meilian Chen, et al. Front Pharmacol. 2025;16(NA).
year: '2025'
doi: 10.3389/fphar.2025.1528208
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media SA
keywords: arrhythmia | astragaloside IV | traditional Chinese medicine | Astragalus
  membranaceus | pharmacological mechanisms
automl_pathway: 0.8745158
figid_alias: PMC12018449__F1
figtype: Figure
redirect_from: /figures/PMC12018449__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12018449__fphar-16-1528208-g001.html
  '@type': Dataset
  description: Mechanisms of AS-IV in the pathogenesis of arrhythmia. Astragaloside
    IV exhibits anti-ischemia-reperfusion injury, anti-ion channel disorder, and anti-myocardial
    fibrosis effects through maintaining mitochondrial quality control, counteracting
    oxidative stress, exerting anti-inflammatory actions, and resisting apoptosis.
    It is capable of inhibiting the expression of Drp1, decreasing the release of
    Cyt C, influencing the opening of mPTP pores, suppressing mitochondrial fission
    and fragmentation, and preserving the integrity of mitochondrial structure and
    function. It can activate the PI3K/AKT//Nrf2/ARE signaling pathway, enhance the
    expression and nuclear translocation efficiency of Nrf2, initiate the expression
    of downstream antioxidant factors, and alleviate oxidative stress. It can restrain
    the activation of the NF-κB/TLR4/NLPR3 signaling pathway, reduce the expression
    of downstream inflammatory factors, and mitigate inflammation. It can inhibit
    the caspase pathway, regulate the expression of Bcl-2/bax, and decrease cardiomyocyte
    apoptosis
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - GAD1
  - GAD2
  - CRMP1
  - UTRN
  - DENR
  - DNM1L
  - DAPK2
  - GSK3A
  - GSK3B
  - BCL2
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - BAX
  - GABPA
  - NFE2L2
  - KEAP1
  - EIF2AK3
  - NLRP3
  - HMOX1
  - GPX1
  - SOD1
  - SOD2
  - SOD3
  - NFKB1
  - MAF
  - MAFA
  - MAFB
  - MAFF
  - MAFG
  - MAFK
  - TLR4
  - HSPA5
  - ERN1
  - IL1A
  - IL1B
  - IL18
  - IL6
  - TNF
  - ROS
  - PERK
  - Nucleus
  - TNF-a
---
